

BrightEdge HAS INVESTED in **18 COMPANIES**
with the **POTENTIAL** to **IMPACT**
1.5M+ PATIENTS* and **THEIR FAMILIES** IN
THE FIGHT AGAINST CANCER

BY THE NUMBERS

ACS Impact Venture Fund **\$78M** GROSS ASSET VALUE

\$28.9M

\$9.7M IN GAINS ON
\$28.9M IN INVESTMENTS


\$3.1B RAISED by portfolio
companies to advance
PATIENT-CENTRIC
INNOVATIONS such as therapeutics,
diagnostics, devices and other technologies

4 NEW INVESTMENTS and **6 FOLLOW-ON** INVESTMENTS ACROSS **5** PORTFOLIO COMPANIES

DEFINING IMPACT AND INNOVATION BY:



Partnering with ACS**
Discovery Research to
narrow the gap between
scientific grantmaking
and **equity investments**.



Identifying and
enabling the next
generation of **cancer-**
fighting entrepreneurs
and **leaders**.



Mobilizing collaborator
networks to **accelerate**
and **deepen impact of**
investments.

BrightEdge, LLC is the American Cancer Society's innovation and impact investing arm.
To learn more about BrightEdge and read the 2022 Annual Report, visit acsbrightedge.org.

*Cancer Impact Investment Framework™ is a proprietary and unique framework that assesses investment impact across American Cancer Society mission priority areas and cancer care continuum
**The American Cancer Society is the leading cancer-fighting organization with a vision of ending cancer as we know it, for everyone. To learn more about ACS, visit cancer.org